DK4214202T3 - Faste former af en cdk4-hæmmer - Google Patents

Faste former af en cdk4-hæmmer Download PDF

Info

Publication number
DK4214202T3
DK4214202T3 DK21783049.6T DK21783049T DK4214202T3 DK 4214202 T3 DK4214202 T3 DK 4214202T3 DK 21783049 T DK21783049 T DK 21783049T DK 4214202 T3 DK4214202 T3 DK 4214202T3
Authority
DK
Denmark
Prior art keywords
solid forms
cdk4 inhibitor
cdk4
inhibitor
solid
Prior art date
Application number
DK21783049.6T
Other languages
Danish (da)
English (en)
Inventor
Wesley Dewitt Clark
Judith Gail Deal
Brian Matthew Samas
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK4214202T3 publication Critical patent/DK4214202T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK21783049.6T 2020-09-15 2021-09-13 Faste former af en cdk4-hæmmer DK4214202T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063078636P 2020-09-15 2020-09-15
US202163240268P 2021-09-02 2021-09-02
PCT/IB2021/058320 WO2022058871A1 (en) 2020-09-15 2021-09-13 Solid forms of a cdk4 inhibitor

Publications (1)

Publication Number Publication Date
DK4214202T3 true DK4214202T3 (da) 2025-03-31

Family

ID=78000744

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21783049.6T DK4214202T3 (da) 2020-09-15 2021-09-13 Faste former af en cdk4-hæmmer

Country Status (18)

Country Link
US (1) US20230357211A1 (OSRAM)
EP (2) EP4214202B1 (OSRAM)
JP (2) JP7260606B2 (OSRAM)
KR (1) KR20230069983A (OSRAM)
CN (1) CN116507620B (OSRAM)
AU (1) AU2021345531B2 (OSRAM)
CA (1) CA3195063A1 (OSRAM)
DK (1) DK4214202T3 (OSRAM)
ES (1) ES3022913T3 (OSRAM)
FI (1) FI4214202T3 (OSRAM)
HU (1) HUE070846T2 (OSRAM)
MX (1) MX2023003054A (OSRAM)
PL (1) PL4214202T3 (OSRAM)
PT (1) PT4214202T (OSRAM)
SI (1) SI4214202T1 (OSRAM)
TW (2) TW202334125A (OSRAM)
WO (1) WO2022058871A1 (OSRAM)
ZA (1) ZA202303655B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
CA3240993A1 (en) * 2021-12-02 2023-06-08 Pfizer Inc Cdk4 inhibitor for the treatment of cancer
CN119604288A (zh) 2022-07-29 2025-03-11 辉瑞大药厂 用于治疗癌症的包含kat6抑制剂的给药方案
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
KR20250164842A (ko) 2023-03-30 2025-11-25 화이자 인코포레이티드 Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법
WO2024246824A1 (en) 2023-06-02 2024-12-05 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
WO2024246825A1 (en) 2023-06-02 2024-12-05 Pfizer Inc. Combinations of estrogen receptor degraders and cdk4 inhibitors
WO2025024388A1 (en) 2023-07-21 2025-01-30 Accutar Biotechnology Inc. Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors
WO2025104624A1 (en) 2023-11-14 2025-05-22 Pfizer Inc. Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol
WO2025202871A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor
WO2025202854A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
WO2025202900A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors for use in the treatment of mantle cell lymphoma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
SG10202012466PA (en) * 2016-07-13 2021-01-28 Syros Pharmaceuticals Inc Inhibitors of cyclin-dependent kinase 7 (cdk7)
UA124804C2 (uk) 2016-08-15 2021-11-24 Пфайзер Інк. Піридопіримідинонові інгібітори cdk2/4/6
CN118286225A (zh) * 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物

Also Published As

Publication number Publication date
EP4214202B1 (en) 2025-02-26
SI4214202T1 (sl) 2025-05-30
JP7260606B2 (ja) 2023-04-18
CA3195063A1 (en) 2022-03-24
ES3022913T3 (en) 2025-05-29
PL4214202T3 (pl) 2025-05-19
AU2021345531A1 (en) 2023-04-20
EP4578450A2 (en) 2025-07-02
HUE070846T2 (hu) 2025-07-28
MX2023003054A (es) 2023-04-05
TW202334125A (zh) 2023-09-01
JP2022049005A (ja) 2022-03-28
JP7291839B2 (ja) 2023-06-15
AU2021345531B2 (en) 2024-02-29
EP4578450A3 (en) 2025-07-16
CN116507620B (zh) 2025-11-18
PT4214202T (pt) 2025-04-11
ZA202303655B (en) 2024-09-25
FI4214202T3 (fi) 2025-04-25
US20230357211A1 (en) 2023-11-09
TW202216698A (zh) 2022-05-01
TWI809503B (zh) 2023-07-21
CN116507620A (zh) 2023-07-28
EP4214202A1 (en) 2023-07-26
JP2022186995A (ja) 2022-12-15
KR20230069983A (ko) 2023-05-19
BR112023004713A2 (pt) 2023-04-18
WO2022058871A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
DK4214202T3 (da) Faste former af en cdk4-hæmmer
DK3880670T3 (da) Forbedret syntese af nøglemellemprodukt af kras-g12c-hæmmerforbindelse
EP3984999A4 (en) ALLOSTERIC INHIBITOR OF PHOSPHATASE SHP2
EP4434979A4 (en) KIF18A INHIBITOR
DK4146348T3 (da) Inhibitorer af nek7-kinase
DK3826982T3 (da) Anvendelse af en substitueret thiazolidinforbindelse som nitrificeringshæmmer
DK3472157T3 (da) Krystallinske faste former af en bet-inhibitor
IL283860A (en) Crystalline forms and salt forms of a kinase inhibitor
EP4332103A4 (en) ATR INHIBITOR COMPOUND CONTAINING A SULFOXIMINE
EP3901156A4 (en) NITROOXY DERIVATIVE OF ROCK KINASE INHIBITOR
EP3986902C0 (en) MACROCYCLIC MCL-1 INHIBITORS
IL282454A (en) Crystalline salts of a plasma kallikrein inhibitor
EP4003986A4 (en) Inhibitor compounds
IL304497A (en) Crystalline forms of a pyrrolopyridine-aniline compound
EP4108666A4 (en) MULTI-TARGETED TYROSINE KINASE INHIBITOR
DK4114826T3 (da) Krystallinske former af en farmaceutisk forbindelse
IL314221A (en) Synthesis of a kif18a inhibitor
ECSP22016209A (es) Síntesis de un inhibidor de calicreína plasmática a escala de proceso
DK3826983T3 (da) Anvendelse af substituerede 2-thiazoliner som nitrificeringshæmmere
DK3974774T3 (da) Opmåling af byggegrube
DK3847175T3 (da) Krystallinske former af en phosphoinositid-3-kinase- (pi3k) inhibitor
DK4288036T3 (da) Formuleringer af en plasmakallikreinhæmmer
DK4387730T3 (da) Faste former af en rock-hæmmer
EP4310086A4 (en) CRYSTALLINE FORM OF A HETEROCYCLIC COMPOUND AS A PROTEIN KINASE INHIBITOR
IT201900025540A1 (it) Tassello a espansione